Increased cervical dysplasia in intravenous cyclophosphamidetreated patients with SLE: a preliminary study

Abstract

To determine if intravenous cyclophosphamide (IV-C) causes an excess of cervical dysplasia and/or cancer in systemic lupus erythematosus (SLE) patients, a retrospective review was conducted. Patients with SLE who received IV-C between 1988–98 (study group) were compared with a group of SLE patients who had not received IV-C (control group).

Of the 79 IV-C-treated SLE patients identified, we excluded 18 because of absence of pertinent data. We found 10 cases of cervical dysplasia in the remaining 61 patients, compared to 2 in 49 non-exposed patients (P < 0.04). Comparison of the two groups revealed no difference in: mean years of disease duration, months of follow-up and age. The non-exposed patients were more likely to be on estrogen and hydroxychloroquine but less often on steroids and azathioprine. The study group with and without dysplasia were assessed; we found no difference in the mean, or total IV-C dose, smoking and estrogen use. There was a significant decrease in time to dysplasia in those, given IV-C, with previous dysplasia compared to those without.

These preliminary data suggests that IV-C causes an increased number of abnormal Papanicolaou (Pap) smears in SLE patients, particularly those with previous dysplasia.

Keywords

SLE cervical dysplasia intravenous cyclosphosphamide

Get full access to this article

View all access options for this article.

References

Ginzler EM . Renal disease in systemic lupus erythematosus. In: Weisman MH , Weinblatt ME (eds) Treatment of the Rheumatic Diseases. V/B Saunders: Philadelphia , 1995, pp 109–127.

Canoso JJ , Cohen AS . Malignancy in a series of 70 patients with systemic lupus erythematosus . Arthritis Rheum 1974; 17: 383–390 .

Lewis RB , Castor CW , Knisley RE , Bole GG . Frequency of neoplasia in systemic lupus erythematosus and rheumatoid arthritis . Arthritis Rheum 1976; 19: 1256–1260 .

Pettersson T , Pukkala B , Teppo L , Friman C . Increased risk of cancer in patients with systemic lupus erythematosus . Ann Rheum Dis 1992; 51: 437–439 .

Nyberg G , Eriksson O , Westberg NG . Increased incidence of cervical atypia in women with systemic lupus erythematosus treated with chemotherapy . Arthritis Rheum 1981; 24: 648–650 .

Gourley MF , Austin HA , Scott D et al. Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. A randomized, controlled trial . Ann Intern Med 1996; 125: 549–557 .

Blumenfeld Z , Lorber M , Yoffe N , Scharf Y . Systemic lupus erythematosus: predisposition for uterine cervical dysplasia . Lupus 1994; 3: 59–61 .

Lima FR , Guerra D , Sella EMC et al. Systemic lupus erythematosus and cervical intraepithelial neoplasia . Arthritis Rheum 1998; 41: 9-9,66-66 (abstract 202).

Bateman H , Yazici Y , Leff L , Paget S . Cervical cancer and dysplasia in intravenous cyclophosphamide-treated patients with SLE . Arthritis Rheum 1998; 41: 9-9, 107-107 (abstract 449).

10.

Centers for Disease Control. National Breast and Cervical Cancer Early Detection Program 1991–97-97.

11.

Ramsey-Goldman R , Mattai SA , Schilling E et al. Increased risk of malignancy in patients with systemic lupus erythematosus . J Invest Med 1998; 46: 217–222 .

12.

Mellemkjaer L , Andersen V , Linet MS et al. Non-Hodgkin's lymphoma and other cancers among a cohort of patients with systemic lupus erythematosus . Arthritis Rheum 1997; 40: 761–768 .

13.

Abu-Shakra M , Gladman DD , Urowitz MB . Malignancy in systemic lupus erythematosus . Arthritis Rheum 1996; 39: 1050–1054 .

14.

Lopez Dupla M , Khamashta M , Pintado Garcia et al. Malignancy in systemic lupus erythematosus: a report of five cases in a series of 96 patients . Lupus 1993; 2: 377–380 .